Addus (ADUS) Q2 2025 Earnings Call Transcript

Addus HomeCare reported Q2 revenue of $349.4 million, up 21.8%, with adjusted EPS of $1.49 (+10.4%) and adjusted EBITDA of $43.9 million (+24.5%), while maintaining an EBITDA margin of 12.6%. Personal Care remained the growth engine, helped by Gentiva and favorable reimbursement increases in Illinois and Texas that should add about $35.2 million of annualized revenue, though home health was down 6% and CMS proposed a 6.4% Medicare payment cut for 2026. The company ended the quarter with $97 million in cash and $173 million of bank debt, and reiterated full-year EBITDA margin guidance of 12%-13%.

Analysis

ADUS is starting to look less like a pure home-care operator and more like a regulated cash-flow compounder with embedded state-mandated earnings growth. The key second-order effect is that Illinois and Texas rate actions effectively de-risk the next 2-3 quarters of organic growth while the company keeps layering on M&A; that creates a rare combo of visible revenue and margin accretion without relying on macro demand. Because the incremental dollars come from states that are explicitly trying to preserve in-home capacity, the pass-through risk is lower than the headline reimbursement numbers suggest.

The more interesting issue is that the market may be underappreciating how much the business mix is shifting toward higher-quality PCS density, which improves acquisition financing capacity and lowers integration risk. Net leverage under 1x gives ADUS optionality to keep buying small assets while the proposed home health cut likely freezes larger competitors and sellers; that should widen the spread between disciplined consolidators and smaller subscale operators. In other words, regulatory pressure in home health can actually become a strategic tailwind for ADUS if it suppresses competition for tuck-ins and slows rival deal activity.

The main risk is timing mismatch: the near-term story is strong, but the most controversial policy items hit later, and the stock can rerate before any state budget pressure shows up in 2028. The consensus may also be too relaxed about hospice and clinical labor; those are the margin friction points that can offset PCS upside if hiring tightens or cap leakage rises. So the trade is not to chase a perfect multiple expansion story, but to own the cash-flow inflection while using policy and valuation as a ceiling, not a floor.

Key Decisions for Investors

• Go long ADUS on any post-earnings/after-rally pullback over the next 1-3 weeks; the setup is favorable as 2025-2026 rate actions and tuck-in M&A should support a multi-quarter earnings grind higher. Best risk/reward is buying weakness, not chasing strength, because the headline multiple can compress if investors fixate on home health policy risk.
• Pair trade: long ADUS / short a lower-quality home health operator with heavier Medicare exposure and less balance sheet flexibility (e.g., short a basket proxy if single-name borrow is tight) for 3-6 months. Thesis: ADUS benefits from state-funded PCS growth while pure home-health names face valuation derating from the proposed 2026 payment cut.
• Consider Jan-2026 or Mar-2026 call spreads on ADUS rather than outright stock if implied vol is reasonable. The catalyst stack is clear over the next 2-4 quarters, but the spread limits downside if policy headlines cause temporary multiple compression.
• If you own ADUS already, take profits only if the stock rerates ahead of confirmation that Texas/Illinois approvals are implemented. The fundamental earnings setup remains constructive into year-end, so the more attractive trim point is a policy-driven spike, not normal operational volatility.